Allogeneic vascularized grafting of human knee joints under postoperative immunosuppression of the recipient.
Vascularized knee joint transplantations have been performed in various animal systems. Up to now no allogeneic vascularized transplantation of a fresh and perfused human knee joint has been realized. This paper reports on the first four grafted human knee joints, performed between April 1996 and July 1997 at the Trauma Center Murnau. The indication for transplantation of a human knee joint is total loss of the joint, including the extensor apparatus, following severe trauma. Management of this defect is first to effect closure of the soft tissue defect combined with external transfixation and bone cement spacers. For the second phase the external stabilization is switched to internal stabilization using femoral tibial nails and a temporary knee joint prosthesis manufactured of polyethylene. The transplantations are performed with respect to ABO compatibility, ignoring the HLA system after a negative crossmatch. Osteosyntheses are employed by femoral and tibial nails. The vascular anastomoses are established in an end-to-side technique between the recipient's superficial femoral vessels and the graft vascular pedicles. Immunosuppression starts as quadruple induction therapy for 3 days. Subsequently it is reduced to a two-drug maintenance protocol with cyclosporin A and azathioprine. We utilize radiography, digital subtraction angiography, duplex sonography, scintigraphy, and arthroscopy for graft monitoring. Six months after transplantation the osteotomies were bridged with callus, and the patients were completely mobilized. The motion in the transplanted knee joint ranges from complete extension to 110 degree flexion.
Hofmann
G O
GO
Trauma Center Murnau, Germany.
Kirschner
M H
MH
Wagner
F D
FD
Brauns
L
L
Gonschorek
O
O
Bühren
V
V
D000293:Adolescent; D000328:Adult; D000714:Anastomosis, Surgical; D016025:Bone Transplantation / Q000000981:diagnostic imaging / Q000379:methods*; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000601:surgery; D005268:Femoral Vein / Q000000981:diagnostic imaging / Q000601:surgery; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007718:Knee Injuries / Q000601:surgery; D007719:Knee Joint / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000098:blood supply / Q000637:transplantation; D011183:Postoperative Complications / Q000276:immunology / Q000517:prevention & control; D011859:Radiography; D016059:Range of Motion, Articular; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D007166:Immunosuppressive Agents